Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–62 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Uveitis; Posterior, Disorder Clear all
Completed Phase 2 Interventional

ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)

NCT02931175
View directory record Official record
Conditions
Uveitis
Interventions
ACTH gel
Drug
Lead sponsor
Quan Dong Nguyen
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Waltham, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Ozurdex for the Control of Uveitis

NCT02049476
View directory record Official record
Conditions
Uveitis, Intermediate, Uveitis, Posterior
Interventions
Dexamethasone pellet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 3, 2026, 9:32 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01090310
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 3, 2026, 9:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Interventions
Brepocitinib PO QD, Placebo PO QD
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
53
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 3, 2026, 9:32 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

NCT01747538
View directory record Official record
Conditions
Uveitis
Interventions
Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

NCT02255032
View directory record Official record
Conditions
Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
Interventions
4 mg CLS-TA, 0.8 mg CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

NCT04976777
View directory record Official record
Conditions
Macular Edema
Interventions
Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
Device · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

NCT01789320
View directory record Official record
Conditions
Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis
Interventions
triamcinolone acetonide (Triesence®)
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 3, 2026, 9:32 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

NCT06085079
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
Ixekizumab Prefilled Syringe
Drug
Lead sponsor
Massachusetts Eye Research and Surgery Institution
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 3, 2026, 9:32 AM EDT
Completed No phase listed Observational

Evaluation and Treatment of Patients With Inflammatory Eye Diseases

NCT00006188
View directory record Official record
Conditions
Choroiditis, Iridocyclitis, Iritis, Retinal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
4 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 3, 2026, 9:32 AM EDT
Withdrawn Phase 3 Interventional

Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

NCT01103024
View directory record Official record
Conditions
Uveitis
Interventions
AIN457, Placebo
Biological
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 3, 2026, 9:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate

NCT01314417
View directory record Official record
Conditions
Non-infectious Intermediate and Posterior Uveitis
Interventions
Methotrexate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Not applicable Interventional

Retisert and Cataract Surgery in Patients With Severe Uveitis

NCT00570830
View directory record Official record
Conditions
Intermediate Uveitis, Posterior Uveitis
Interventions
Retisert (fluocinolone acetonide implant)
Device
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 3, 2026, 9:32 AM EDT